[go: up one dir, main page]

CO2018010855A2 - New anti-sirpa antibodies and their therapeutic applications - Google Patents

New anti-sirpa antibodies and their therapeutic applications

Info

Publication number
CO2018010855A2
CO2018010855A2 CONC2018/0010855A CO2018010855A CO2018010855A2 CO 2018010855 A2 CO2018010855 A2 CO 2018010855A2 CO 2018010855 A CO2018010855 A CO 2018010855A CO 2018010855 A2 CO2018010855 A2 CO 2018010855A2
Authority
CO
Colombia
Prior art keywords
new anti
therapeutic applications
sirpa antibodies
sirpa
interaction
Prior art date
Application number
CONC2018/0010855A
Other languages
Spanish (es)
Inventor
Nicolas Poirier
Caroline Mary
Bernard Vanhove
Vanessa Gauttier
Virginie Thepenier
Sabrina Pengam
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of CO2018010855A2 publication Critical patent/CO2018010855A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona nuevos anticuerpos anti-SIRPa capaces de antagonizar específicamente la interacción entre SIRPa y CD47, sin afectar la interacción entre SIRPg y CD47, y sus usos.The present invention provides new anti-SIRPa antibodies capable of specifically antagonizing the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.

CONC2018/0010855A 2016-04-14 2018-10-10 New anti-sirpa antibodies and their therapeutic applications CO2018010855A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
EP17305182 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Publications (1)

Publication Number Publication Date
CO2018010855A2 true CO2018010855A2 (en) 2018-11-13

Family

ID=58185461

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010855A CO2018010855A2 (en) 2016-04-14 2018-10-10 New anti-sirpa antibodies and their therapeutic applications

Country Status (11)

Country Link
EP (1) EP3443010B1 (en)
CN (1) CN109071664B (en)
AU (1) AU2017248626B2 (en)
BR (1) BR112018070823A2 (en)
CA (1) CA3020373A1 (en)
CO (1) CO2018010855A2 (en)
EA (1) EA201891882A1 (en)
PE (1) PE20181921A1 (en)
PT (1) PT3443010T (en)
SG (1) SG11201808465UA (en)
WO (1) WO2017178653A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486329B2 (en) 2018-07-10 2025-12-02 National University Corporation Kobe University Anti-SIRPα antibody

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY185014A (en) 2015-08-07 2021-04-30 Alx Oncology Inc Contructs having a sirp-alpha domain or variant thereof
MD3443010T2 (en) 2016-04-14 2024-12-31 Ose Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
JP7173971B2 (en) 2016-12-09 2022-11-16 アレクトル エルエルシー ANTI-SIRP-α ANTIBODY AND METHOD OF USE THEREOF
KR20190117670A (en) * 2017-02-17 2019-10-16 오제 이뮈노테라프틱스 New Uses of Anti-SIRPg Antibodies
IL315837A (en) 2017-04-13 2024-11-01 Sairopa B V Anti-sirp alpha antibodies
US11203611B2 (en) 2017-04-14 2021-12-21 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
DK3625259T3 (en) * 2017-05-16 2024-07-08 Byondis Bv ANTI-SIRPALPHA ANTIBODIES
SG11202000053TA (en) 2017-08-02 2020-02-27 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
CN111278865B (en) * 2017-10-26 2023-04-25 盛禾(中国)生物制药有限公司 Novel recombinant fusion proteins, their preparation and use
EP3765512A1 (en) 2018-03-13 2021-01-20 OSE Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
CN112566642B (en) 2018-03-14 2025-01-17 纪念斯隆凯特琳癌症中心 Anti-polysialic acid antibodies and uses thereof
US11292850B2 (en) * 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
UA128113C2 (en) 2018-05-25 2024-04-10 ЕЛЕКТОР ЕлЕлСі ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
MY205933A (en) * 2018-09-27 2024-11-21 Celgene Corp Sirp-alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020091596A1 (en) 2018-10-29 2020-05-07 Umc Utrecht Holding B.V. Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
EP3880239A4 (en) * 2018-11-14 2022-11-23 Arch Oncology, Inc. THERAPEUTIC SIRPalpha ANTIBODIES
SG11202104431PA (en) * 2018-11-15 2021-05-28 Byondis Bv HUMANIZED ANTI-SIRPα ANTIBODIES
PH12021551425A1 (en) * 2018-12-21 2022-05-02 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
US20220143210A1 (en) * 2019-02-27 2022-05-12 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatement of malignancies
CN113784984A (en) * 2019-03-04 2021-12-10 齐鲁普吉湾生物治疗公司 anti-SIRP alpha antibodies
MX2021014627A (en) 2019-05-31 2022-01-06 Alx Oncology Inc MASKED CYTOKINE POLYPEPTIDES.
JP7561775B2 (en) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド Methods and reagents for reducing interference of drugs that bind to CD47 in serological assays - Patents.com
EP3756688A1 (en) 2019-06-25 2020-12-30 Université de Nantes Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
MX2021015452A (en) 2019-06-25 2022-02-11 Gilead Sciences Inc FLT3L-FC FUSION PROTEINS AND METHODS OF USE.
CN112867507B (en) * 2019-08-20 2025-03-04 科望(苏州)生物医药科技有限公司 Novel anti-SIRPA antibodies
ES2973832T3 (en) 2019-10-18 2024-06-24 Forty Seven Inc Combination therapies for the treatment of myelodysplastic syndromes and acute myeloid leukemia
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
US20210154269A1 (en) 2019-11-27 2021-05-27 ALX Oncology Inc. Combination therapies for treating cancer
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Diacylglycerol kinase modulating compounds
CN111116713B (en) * 2020-01-07 2023-06-23 郑州大学 Sirpa protein affinity cyclic peptide and application thereof
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
MX2022010515A (en) 2020-02-28 2022-11-14 Tallac Therapeutics Inc CONJUGATION MEDIATED BY TRANSGLUTAMINASE.
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
CN115666620A (en) 2020-06-01 2023-01-31 Alx肿瘤生物技术公司 Combination therapies comprising hypomethylating agents for the treatment of cancer
JPWO2022102634A1 (en) 2020-11-11 2022-05-19
US20240018255A1 (en) 2020-11-30 2024-01-18 Qure Biotechnology (Shanghai) Co., Ltd. ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
JP2024520902A (en) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド Combination Therapies for Treating Cancer
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022247933A1 (en) * 2021-05-28 2022-12-01 百奥泰生物制药股份有限公司 ANTI-SIRPα ANTIBODY AND USE THEREOF
CA3218692A1 (en) 2021-06-04 2022-12-08 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023020459A1 (en) 2021-08-17 2023-02-23 杭州九源基因工程有限公司 MONOCLONAL ANTIBODY TARGETING SIRPα AND USE THEREOF
JP2024539252A (en) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド Pyridin-3(2H)-one derivatives
PE20241186A1 (en) 2021-10-29 2024-06-03 Gilead Sciences Inc CD73 COMPOUNDS
US20250340632A1 (en) 2021-11-29 2025-11-06 Ose Immunotherapeutics SPECIFIC ANTAGONIST ANTI-SIRPg ANTIBODIES
JP2024546851A (en) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
PL4245756T3 (en) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (en) 2022-04-05 2025-03-11 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
CA3249472A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN119136832A (en) 2022-05-10 2024-12-13 第一三共株式会社 Combination of Antibody-Drug Conjugates with Anti-SIRPα Antibodies
JP2025523369A (en) 2022-06-01 2025-07-23 エーエルエックス オンコロジー インコーポレイテッド Combination Therapy for Treating Urothelial Carcinoma
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
CN120225509A (en) 2022-12-22 2025-06-27 吉利德科学公司 PRMT5 inhibitors and uses thereof
CN121358499A (en) 2023-03-30 2026-01-16 Ose免疫疗法 Lipid-based nanoparticles targeting activated immune cells to express immune cell-enhancing molecules and their applications
CN121335715A (en) 2023-03-30 2026-01-13 Ose免疫疗法 Synthesis method and application of targeting lipid nanoparticle
CN120882725A (en) 2023-04-11 2025-10-31 吉利德科学公司 KRAS-regulated compounds
KR20250175331A (en) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 PRMT5 inhibitors and uses thereof
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN119192379B (en) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 A high-affinity anti-SIRPγ monoclonal antibody and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CN103242444A (en) * 2007-10-11 2013-08-14 大学健康网络 Modulation of SIRP-alpha - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CN101780283A (en) * 2010-03-16 2010-07-21 中国人民解放军第二军医大学 Application of signal adjusting protein alpha in preparation of DC vaccine for preventing and treating tumors
CN101880324B (en) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 A kind of anti-human SIRPα monoclonal antibody and its cell line, preparation method and application
EP3116544A4 (en) * 2014-03-11 2017-08-23 The Board of Trustees of the Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486329B2 (en) 2018-07-10 2025-12-02 National University Corporation Kobe University Anti-SIRPα antibody

Also Published As

Publication number Publication date
CA3020373A1 (en) 2017-10-19
PT3443010T (en) 2024-10-21
EP3443010B1 (en) 2024-08-07
EA201891882A1 (en) 2019-07-31
SG11201808465UA (en) 2018-10-30
EP3443010A2 (en) 2019-02-20
WO2017178653A3 (en) 2018-07-05
AU2017248626B2 (en) 2024-05-09
PE20181921A1 (en) 2018-12-11
AU2017248626A1 (en) 2018-10-11
BR112018070823A2 (en) 2019-02-05
CN109071664B (en) 2023-02-21
WO2017178653A2 (en) 2017-10-19
CN109071664A (en) 2018-12-21

Similar Documents

Publication Publication Date Title
CO2018010855A2 (en) New anti-sirpa antibodies and their therapeutic applications
MX2018012434A (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS.
CL2019000424A1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof.
CR20170240A (en) ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES
CL2019002824A1 (en) Anti-lag3 antibodies.
MX2024000300A (en) Anti-tau antibodies and methods of use.
TR201810635T4 (en) Anti-jagged1 antibodies and methods of use.
MX384364B (en) ANTI-PD-L1 ANTIBODIES AND THEIR DIAGNOSTIC USES.
MX387587B (en) SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND THEIR USES.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EA202092435A2 (en) MONOCLONAL ANTIBODIES AGAINST BCMA
MY198059A (en) Anti-ox40 antibodies and their uses
EA201790984A1 (en) ANTI-CD79B ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2017005920A (en) Anti-tim3 antibodies and methods of use.
EP4465050A3 (en) Anti-tau antibodies and methods of use
MX2019006330A (en) Anti-tau antibodies and methods of their use.
MX393455B (en) ANTI-CD40 ANTIBODIES AND THEIR USES.
EA201691991A1 (en) MULTI-SPECIFIC ANTIBODIES
BR112017007170A2 (en) humanized anti-ox40 antibodies and their uses
MX389001B (en) SESTRIN-GATOR2 INTERACTION MODULATORS AND THEIR USES.
CL2018001279A1 (en) Spodoptera frugiperda resistant to vip3a.
MX2016016233A (en) ANTI-LGR5 ANTIBODIES AND ITS USES.
BR112017019176A2 (en) processes for the preparation of fluorocetolides
CL2021002836A1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations of these (divisional of application no. 201900424)
MY195448A (en) New Anti-Sirpa Antibodies and Their Therapeutic Applications